Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions AUD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 8, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	9,055	8,238	3,263	2,300	2,209	1,060
Market Cap Growth	152.44%	152.44%	41.89%	4.10%	108.44%	169.99%
Enterprise Value	8,926	8,141	3,145	2,180	2,161	1,039
Last Close Price	26.80	24.61	10.08	7.27	7.75	3.78
PE Ratio	185.34	165.02	626.21	-	-	-
Forward PE	63.30	87.27	32.83	-	-	-
PS Ratio	11.56	10.52	6.49	14.37	290.85	203.33
PB Ratio	15.94	14.50	21.91	28.75	1023.78	13.41
P/TBV Ratio	59.54	54.17	83.14	109.40	-	53.46
P/FCF Ratio	635.54	578.16	229.72	-	-	619.12
P/OCF Ratio	210.44	191.44	136.63	-	-	540.78
EV/Sales Ratio	11.40	10.39	6.26	13.62	284.54	199.24
EV/EBITDA Ratio	99.28	92.95	55.00	-	-	-
EV/EBIT Ratio	108.99	99.41	60.60	-	-	-
EV/FCF Ratio	626.49	571.37	221.37	-	-	606.68
Debt / Equity Ratio	1.02	1.02	0.12	0.13	1.18	0.03
Debt / EBITDA Ratio	6.47	6.47	0.30	-	-	-
Debt / FCF Ratio	40.81	40.81	1.23	-	-	1.29
Asset Turnover	0.82	0.82	1.52	0.88	0.06	0.04
Inventory Turnover	10.79	10.79	15.36	10.92	1.25	3.45
Quick Ratio	2.60	2.60	1.18	1.90	1.13	4.62
Current Ratio	2.78	2.78	1.41	2.03	1.25	4.69
Return on Equity (ROE)	13.92%	13.92%	4.55%	-253.34%	-198.36%	-60.21%
Return on Assets (ROA)	5.33%	5.33%	9.81%	-25.37%	-37.95%	-23.64%
Return on Capital (ROIC)	7.78%	7.78%	25.26%	-97.35%	-118.20%	-40.13%
Return on Capital Employed (ROCE)	6.90%	6.90%	21.50%	-	-	-
Earnings Yield	0.55%	0.61%	0.16%	-4.53%	-3.64%	-4.23%
FCF Yield	0.16%	0.17%	0.43%	-3.09%	-2.75%	0.16%
Buyback Yield / Dilution	-6.64%	-6.64%	-4.21%	-10.08%	-9.69%	-10.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.